Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema
Roderick O'Day,1 Daniel Barthelmes,1 Meidong Zhu,1 Tien Yin Wong,2,3 Ian L McAllister,4 Jennifer J Arnold,5 Mark C Gillies11Clinical Ophthalmology and Eye Health, The University of Sydney, Sydney, NSW, Australia; 2Singapore Eye Research Institute, National University of Singapore, Singapore;...
Guardado en:
Autores principales: | O'Day R, Barthelmes D, Zhu M, Wong TY, McAllister IL, Arnold JJ, Gillies MC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/87f7e92b53fe4921b5c3c705d6878603 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal triamcinolone for intraocular inflammation and associated macular edema
por: Steven M Couch, et al.
Publicado: (2008) -
EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
por: Ume Sughra, et al.
Publicado: (2021) -
Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
por: Javier Obis, et al.
Publicado: (2021) -
Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal).
por: Francesco Saverio Sorrentino, et al.
Publicado: (2021) -
Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
por: Marey HM, et al.
Publicado: (2011)